

Freedom of Information Request: Our Reference CTMUHB_552_24

You asked:

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

77 patients. CTMUHB also refers multiple myeloma patients to University Hospital Wales for therapies marked with an asterisk (*) below.

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- **Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) = 0**
- **Bortezomib, thalidomide and dexamethasone [VTD] = 0**
- **Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone = 9**
- **Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) = 9**
- **Selinexor, Bortezomib [Velcade] and dexamethasone = 0**
- **Carfilzomib [Kyprolis] and dexamethasone = 0**
- **Bortezomib [Velcade] monotherapy or with dexamethasone = 0**
- **Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVD or DBd) = 19**
- **Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone = 0**
- **Belantamab Mafodotin [Blenrep] = 0**
- **Idecabtagene vicleucel [Abecma] = 0***
- **Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) = 0**
- **Elranatamab = 0***
- **Daratumumab [Darzalex] monotherapy = Less than 5**
- **Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) = 12**
- **Lenalidomide [Revlimid] and dexamethasone = 10**
- **Lenalidomide [Revlimid] monotherapy = 10**
- **Pomalidomide [Imnovid] and dexamethasone = 6**
- **Selinexor and dexamethasone = 0**
- **Talquetamab = 0***
- **Teclistamab [Tecvayli] = 0***
- **Any other systemic anti-cancer therapy**
 - **Bendamustine = Less than 5**
 - **PanBorDex = Less than 5**

Please note:

- CTMUHB also refers multiple myeloma patients to University Hospital Wales for therapies marked with an asterisk (*)
- Some patients may have received more than one treatment line in this time period.
- Less than 5 – exact figures have been withheld due to the low numbers involved. This is due to the potential risk of identification if we released the number of patients for the specific year who have been admitted with this condition, which might then be linked with other information available in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.